TAILIEUCHUNG - Báo cáo khoa học: A study of microRNAs in silico and in vivo: diagnostic and therapeutic applications in cancer

There is emerging evidence of the production in human tumors of abnormal levels of microRNAs (miRNAs), which have been assigned oncogenic and⁄or tumor-suppressor functions. While some miRNAs commonly exhibit altered amounts across tumors, more often, different tumor types produce unique patterns of miRNAs, related to their tissue of origin. | ỊFEBS Journal MINIREVIEW A study of microRNAs in silico and in vivo diagnostic and therapeutic applications in cancer Scott A. Waldman1 and Andre Terzic2 1 Departments of Pharmacology and ExperimentalTherapeutics and Medicine Thomas Jefferson University Philadelphia PA USA 2 Departments of Medicine Molecular Pharmacology ExperimentalTherapeutics and MedicalGenetics Mayo Clinic Rochester MN USA Keywords biomarkers cancer diagnosis individualized therapy microRNA prediction prognosis Correspondence S. A. Waldman 132 South 10th Street 1170 Main Philadelphia PA 19107 USA Fax 1 215 955 5681 Tel 1 215 955 6086 E-mail Received 28 August 2008 revised 7 December 2008 accepted 9 January 2009 doi There is emerging evidence of the production in human tumors of abnormal levels of microRNAs miRNAs which have been assigned oncogenic and or tumor-suppressor functions. While some miRNAs commonly exhibit altered amounts across tumors more often different tumor types produce unique patterns of miRNAs related to their tissue of origin. The role of miRNAs in tumorigenesis underscores their value as mechanism-based therapeutic targets in cancer. Similarly unique patterns of altered levels of miRNA production provide fingerprints that may serve as molecular biomarkers for tumor diagnosis classification prognosis of diseasespecific outcomes and prediction of therapeutic responses. Cancer is a leading cause of mortality in the USA with 25 of deaths attributable to neoplasia 1 2 . Worldwide cancer-related global mortality follows only cardiovascular and infectious diseases 3 . In this context of expanded incidence and growing prevalence clinical oncology is poised for unprecedented innovation. Through harnessing discoveries in disease patho-biology increasingly propelled by the development of high-throughput technologies including genomics proteomics and metabolomics modern cancer biology offers previously unavailable diagnostic .

TỪ KHÓA LIÊN QUAN
Đã phát hiện trình chặn quảng cáo AdBlock
Trang web này phụ thuộc vào doanh thu từ số lần hiển thị quảng cáo để tồn tại. Vui lòng tắt trình chặn quảng cáo của bạn hoặc tạm dừng tính năng chặn quảng cáo cho trang web này.